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A B S T R A C T
The aim of this study was to enhance oral bioavailability of itraconazole (ITZ) by develop-
ing Liposome containing sodium deoxycholate (ITZ-Lip-NaDC). The liposome, consisting of
egg yolk lecithin and sodium deoxycholate, was prepared by thin-film dispersion method.
Differential Scanning Calorimetry (DSC) results indicated an amorphous state in the lipo-
some.The physicochemical characteristics including particle size, morphology, entrapment
efficiency, dissolution properties were also investigated.The performance of single-pass in-
testinal infusion exhibited that the transport order of intestinal segment was jejunum,
duodenum, colon and ileum, and that all the segments participated in the absorption of
ITZ in intestinal tract. The bioavailability study in rats showed that the AUC0-72 of the lipo-
some was nearly 1.67-fold higher than that of commercial capsules (SPORANOX) in terms
of oral administration, and the RSD of AUC0-72 of ITZ-Lip-NaDC was also decreased. Our results
indicated that ITZ-Lip-NaDC liposome was facilitated to improve dissolution efficiency,
augment transmembrane absorption, and then enhance the oral bioavailability of ITZ,
successfully.
© 2017 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. This
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1. Introduction
Itraconazole (ITZ) is widely employed in the treatment of fungal
infections, especially in the cure of histoplasmosis, blastomy-
cosis and refractory aspergillosis [1–3]. Despite effective anti-
fungal therapy, oral bioavailability of ITZ is still restricted by
its extremely poor water solubility, which hinders the further
clinical application of ITZ [4–7].
In order to address these challenges, much effort about
preparations has been paid on ITZ to enhance its aqueous
solubility, dissolution/release, and ultimately improving
bioavailability, such as intravenous emulsion, microemulsion,
nanoemulsion, solid dispersion, gelatin microcapsule, floccu-
lated amorphous nanoparticles, nanosuspensions, nanocrystal,
cyclodextrin complexes, polymeric micelles, itraconazole/
Soluplus extrudate and liposomes [1–3,5,6,8–18]. Among these,
itraconazole/Soluplus extrudate formulated by Zhang et al. dem-
onstrated that the AUC0-48h were 6.9-times higher than those
of pure ITZ. However, the oral bioavailability of ITZ/Soluplus
was similar to commercial Sporanox(R) capsule. Maria et al.
utilized flocculated amorphous itraconazole nanoparticles to
enhance in vitro supersaturation and improved nearly 2-fold
high bioavailability than Sporanox capsules, but the particle
size was about 1000 nm upon dispersion at pH 6.8, which might
hinder its absorption transportation across intestinal mem-
brane. Meanwhile, cyclodextrin–water soluble polymer ternary
complexes were also emerging, which revealed advanced solu-
bility and dissolution behavior; however, the increased
bioavailability of itraconazole was only predicted based on phar-
macokinetic in silico model and the usage of cyclodextrins
might only be slightly suitable for patients who suffered from
kidney failure or renal insufficiency.To correspond to the pre-
dicted pharmacokinetic results, nanocrystal-based per-oral
itraconazole prepared by Sarnes et al. also exhibited superior
dissolution behavior by means of nanosized formulations, but
the effective in vivo drug absorption was not realized in com-
parison with Commercial oral Sporanox® capsules. In spite of
all of the approaches performed to overcome the unsatisfied
bioavailability, the oral liposome encapsulating ITZ has been
poorly reported.
Liposomes, exhibiting the advantage of encapsulating various
drug entities, excellent bioavailability/non-immunogenicity and
intrinsic biocompatibility, represent as an important delivery
system to package drugs in lipid bilayer with a range of several
nanometers tomicrometers [19]. Sodium deoxycholate has been
utilized as a pharmaceutical penetration enhancer for drugs
administered via many routes, including the oral route and it
is generally considered that the ability of bile salts to act as
penetration enhancers is due to the membrane destabilizing
activities of these agents [20–22]. Guan et al. evaluate lipo-
somes containing sodium deoxycholate (SDC), as oral drug
delivery systems to enhance the oral bioavailability, and in-
dicated that SDC facilitated the absorption of liposomes vehicle
[23].
Based on the above considerations, the study mainly aimed
to enhance oral bioavailability of itraconazole (ITZ) by devel-
oping Deoxycholate-Modified Liposome (ITZ-Lip-NaDC), which
consisted of egg yolk lecithin and sodium deoxycholate. We
formulated the liposomes by thin-film dispersion method, and
DSC was applied to demonstrate the state of ITZ in the lipo-
somes. Then the physicochemical properties, stability,
dissolution properties in vitro and pharmacokinetic behavior
were also evaluated.
2. Materials and methods
2.1. Materials
ITZ was supplied from Wan’an Shanghai biological technol-
ogy Co., LTD (Shanghai, China). Egg yolk lecithin and sodium
deoxycholate were provided by Beijing AOBOX biological tech-
nology Co., LTD (Beijing, China). Cholesterol was obtained by
Tianjin Bodi chemical Co., LTD (Tianjin, China). All other chemi-
cals were of reagent grade. All solvents were of HPLC grade
without purification.
2.2. Preparation of ITZ-Lip-NaDC
ITZ-Lip-NaDCwas prepared by thin-film dispersionmethod [18].
Egg yolk lecithin, 300 mg, cholesterol, 37.5 mg, ITZ, 30 mg and
Vitamin E, 3 mg, were mixed and dissolved in dehydrated
dichloromethane. Then, the organic solvent was removed by
rotary vacuum evaporation (E-52A, Yarong, Shanghai, China)
at a 30 °C water bath (HH-2, Guohua, Changzhou, China). 5 mg/
mL sodium deoxycholate solution was employed to hydrate
the thin films, stirring for 4 h at 40 °C. The hydrated lipo-
somes were homogenized by a miniprobe sonography (JY92-
2D, Xinzhi, Ningbo, China) for 5 min at 300 W and filtered
through a 0.22 μm filter to obtain the ultimate concentration
of about 3 mg/mL formulations. Blank liposomes were
prepared in the same way except ITZ [24]. The liposome for-
mulation was lyophilized to facilitate the storage under the
protection of maltose.
2.3. Characterizations of ITZ-Lip-NaDC
2.3.1. Particle size and Zeta potential measurement
The particle size and Zeta potential of liposome formulation
and re-suspended frozen formulation were measured by
dynamic light scattering (DLS) method with a zetasizer in-
strument (Nano ZS, Malvern Co., UK) [4,25].
2.3.2. Morphologic observation
The morphological image of ITZ-Lip-NaDC was obtained by a
transmission electron microscope (TEM) (H-600, Hitachi, Japan).
A drop of ITZ-Lip-NaDC solution was deposited on a carbon-
coated copper grid, and excess solution was tapped with filter
papers. Then the thin-film solution was dried at room tem-
perature, stained with 0.2% phosphotungstic acid aqueous
solutions for 1 min before observation under TEM [4,26].
2.4. Entrapment efficiency
Entrapment efficiency of ITZ-Lip-NaDC was determined with
UV-vis at absorption wavelength of 262 nm. Briefly, SephadexG-
50 was swelled overnight and packed in a 2 mL syringe with
filter paper in the bottom to obtain gel column. Then 200 μL
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ITZ-Lip-NaDC was added onto the gel column and centri-
fuged (13,000 rpm, 20min) to collect the elution. Next, the eluent
and 200 μL ITZ-Lip-NaDC were dissolved in a 25 mL volumet-
ric flask with methanol to detect the content of ITZ in liposome
and total ITZ weight in the liposome formulation, respec-
tively. The entrapment efficiency (EE%) was calculated as:
EE W Win tot% %= × 100
whereWin andWtot are the content of ITZ in liposome and total
ITZ weight in the liposome formulation, respectively.
2.5. DSC analysis
DSC curves of raw material, Lip-NaDC, ITZ-Lip-NaDC as well
as the physical mixtures were performed using a DSC-60
(Mettler-ToledoInternational Inc., Switzerland).Aluminum oxide
was used as a reference standard. Samples (about 2 mg) were
accurately weighed and sealed in aluminum pans. Then,
the samples were heated over the range 30–200 °C at a rate of
10 °C/min [27].
2.6. Stability of of ITZ-Lip-NaDC
The stability study of ITZ-Lip-NaDC was evaluated at differ-
ent temperatures including 4 °C and 37 °C for five days. Changes
in particle size and encapsulated efficiency were selected to
assess the stability of liposomes [28].
2.7. Dissolution test
Dissolution of ITZ-Lip-NaDC lyophilized powder was per-
formed using a ZRS-G8 instrument (Tianjin Tianda Tianfa
Technology Co.,Ltd.,Tianjin, China), taking the commercial cap-
sules (SPORANOX, Xian-Janssen Pharmaceutical Ltd., China) as
control [29]. The dissolution media were 900 mL phosphate
buffers with different pH values, including pH 1.2, pH 2.5, pH
4.0, pH 5.5 and pH 6.8.The rotary speed of the paddles was set
to 75 rpm. Five milliliters of samples were withdrawn at 5, 10,
15, 20, 30, 45, 60 and 90 min, and replaced with 5 mL of fresh
medium to keep the volume constant. After being com-
pletely dissolved in methanol, the concentration of dissolution
samples of ITZ-Lip-NaDC lyophilized powder was performed
using UV-vis at an absorption wavelength of 262 nm.
2.8. In situ single-pass intestinal perfusion of
ITZ-Lip-NaDC liposome in rats
Healthy male Sprague–Dawley rats were obtained from the
animal center of Shenyang Pharmaceutical University.
The animal studies were approved by the Shenyang Pharma-
ceutical University Animal Care and Use Committee.
Sprague−Dawley rats of about 220 g were made to fast, having
access to water for 12 h before perfusion experiment. After in-
traperitoneal injection of 20% urethane (1 g/kg), the rats were
restrained on a warming pad to keep body temperature. Then
a gentle incision along midline was opened, and intestinal seg-
ments including duodenum, jejunum, ileum and colon were
pulled out carefully, which were rinsed with freshly prepared
Krebs Ringer’s (KR) buffer solution (7.8 g of NaCl, 0.35 g of KCl,
1.37 g of NaHCO3, 0.02 g of MgCl2, 0.32 g of NaH2PO4, 1.4 g of
glucose, and 0.32 g of CaCl2 in 1000 mL of purified water) and
balanced at a constant flow rate (Q) of 0.2 mL/min using peri-
staltic pump. ITZ-Lip-NaDC liposome solution and ITZ-HP-β-
CD solution (dissolved in 30 g/L HP-β-CD KR buffer solution)
were dispersed in KR buffer solution to achieve a final con-
centration equivalent to 40 μg/mL of ITZ.The exposed incision
was covered with sterilized cotton to maintain intestinal seg-
ments moist. Finally the animal was executed; the length and
radius of the infused segments were measured precisely. The
absorption rate (Ka) and apparent permeability (Papp) of ITZ-
Lip-NaDC liposome solution and ITZ-HP-β-CD solution in the
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where Cout is the ITZ concentration in the receptor tube, Vout
is the ITZ volume in the receptor tube, Cin is the ITZ concen-
tration in the donor solution, Vin is the ITZ volume in the donor
solution and Q is the perfusion flow rate, and r is the intesti-
nal radius and L is the length of infusion segment [30].
In addition, to investigate the effect of ITZ concentration
on intestinal perfusion, 20 μg/mL and 80 μg/mL ITZ-Lip-
NaDC liposome formulations were also evaluated.
2.9. Pharmacokinetic study in vivo
The rats, with weights of 180–220 g, were randomly divided into
four groups and fasted overnight prior to the experiment
with access to water. Two groups of rats were orally adminis-
trated with ITZ-Lip-NaDC solution and commercial capsules
suspension (dispersed into saline) at a dose of 20 mg/kg.At pre-
determined time points, 0.3 mL of blood samples was collected
and centrifuged at 13,000 rpm for 10 min, then plasma was
frozen at −80 °C. The concentration of ITZ was determined by
UPLC-MS/MS(HPLC-ZQ2000 MS, Waters, USA), coupled with
ACQUITY UPLCTM BEH C18 chromatographic column
(50 mm × 2.1 mm, 1.7 μm,Waters Corp, Milford, MA, USA). The
mobile phase consisted of water containing 0.2% formic acid
and acetonitrile containing 0.2% formic acid (70:30, v/v) at a
flow rate of 0.3 mL/min, and the column temperature was sus-
tained at 40 °C. Quantitation of ITZ was performed using
multiple reactions monitoring of the transition of m/z: 705.78-
392.40 for ITZ and 285.07-193.03 for Diazepam (internal
standard) during investigation. The concentration of each
sample that was calculated referred to a calibration curve with
the concentration range from 10 to 3000 ng/mL with a corre-
lation coefficient of 0.997. The related pharmacokinetic
parameters were achieved using DAS 2.0 software [4,31].
2.10. Statistical data analysis
The results were listed as mean or mean± standard
deviation (SD). Statistical data analysis was carried out using
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one-way ANOVA. Difference was set as significance at
a level of P < 0.05, and a high significance was considered as
P < 0.01.
3. Results and discussions
3.1. Preparation and characterization of ITZ-Lip-NaDC
ITZ-Lip-NaDC was prepared by thin-film dispersion method in
this study, where sodium deoxycholate was applied to modify
ITZ-Lip to improve oral bioavailability of ITZ [23]. As shown in
Fig. 1 and Table 1, the liposome formulation was in good spheri-
cal shape with 118.1 ± 2.0 nm size and −21.5 ± 1.3 mV zeta
potential. However, the study of stability indicated that the li-
posome was unstable either at 4 °C or room temperature. As
demonstrated in Fig. 2, the size of ITZ-Lip-NaDC increased to
around 3-fold of the initial size and the entrapment
efficiency decreased from 92.7% to 79% after 5 days. To
address the unsatisfied stability, maltose was employed as
cryoprotectant in frozen drying process, resulting in about
165.0 ± 2.5 nm obtained liposome size, which wasmore uniform
(slightly larger) after re-suspended in PBS than fresh prepa-
ration, as illustrated in Fig. 1. The size distribution and
encapsulated efficiency of lyophilizated ITZ-Lip-NaDC after
sealed storage in darkness for 1 month were nearly the
same with the evaluation of its re-dissolving without
reservation.
Fig. 1 – Intensity-size distribution of ITZ-Lip-NaDC (A) re-suspended ITZ-LIP-DC (B) and transmission electron microscopy
(TEM) image of ITZ-Lip-NaDC (C) re-suspended ITZ-LIP-DC (D), respectively.
Table 1 – Size, zeta potential and encapsulation
efficiency of ITZ-Lip-NaDC and re-dissolved ITZ-Lip-





Particle size (nm) 118.1 ± 2.0 165.0 ± 2.5
Zeta potential (mV) −21.5 ± 1.3 −25.1 ± 1.6
Entrapment efficiency (%) 90.61 ± 0.66 88.4 ± 0.4
Fig. 2 – Size and encapsulation efficiency changes of ITZ-
Lip-NaDC in PBS 7.4 at 4 °C (A) and 37 °C (B) for 5 d (n = 3).
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3.2. Dissolution properties in vitro
Fig. 3 shows the different dissolution profiles of commercial
capsules and ITZ-Lip-NaDC lyophilized powder.At pH 1.2, com-
mercial capsules appeared to have a faster dissolution rate than
ITZ-Lip-NaDC lyophilized powder.The cumulative released per-
centage of commercial capsules was nearly 100% after 45 min,
while corresponding values were less than 40% in 120 min. In-
teresting, ITZ amounts dissolved from ITZ-Lip-NaDC lyophilized
powder were significantly higher than commercial capsules with
the improvement of pH, as indicated in Fig. 3. When pH was
up to 5.5 or 6.8, the ITZ of ITZ-Lip-NaDC was released com-
pletely in 15 min, but the released amount of the commercial
capsules was only 2% after 120 min. ITZ is a lipophilic alka-
line exhibiting insoluble characteristic in phosphate buffer (pH
4.0), but it could form hydrochloride in lower pH to achieve a
higher solubility [32]. Solid dispersion technique was utilized
in the preparation of commercial capsule by spraying the
mixture of ITZ and HPMC to blank sugar pills, thus its disso-
lution could be easily changed according to pH [33,34].
Compared with commercial capsules, the encapsulated ITZ
in ITZ-Lip-NaDC was less affected because of the external
shell protection of ITZ-Lip-NaDC. Meanwhile, the DSC results
from Fig. 4 revealed that ITZ exist in the form of amorphous
state in the liposome. Hence, it maybe speculated that the
Fig. 3 – Dissolution profiles of ITZ-Lip-NaDC liposomes (A) and commercial capsules (B) in pH1.2, pH2.5, pH 4.0, pH 5.5, and
pH 6.8 PBS (n = 3).
Fig. 4 – DSC thermograms of ITZ, ITZ-Lip-NaDC, Lip-DC and
the physical mixture of ITZ and Lip-DC.
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significant improvement of the dissolution efficiency of ITZ-
Lip-NaDC might be ascribed to amorphous form of ITZ in
liposome.
3.3. In situ single-pass intestinal infusion of
ITZ-Lip-NaDC in rats
The in situ single-pass intestinal infusion model in rats was
used to evaluate the membrane permeability of ITZ-Lip-
NaDC. As shown in Fig. 5 and Fig. S1, the absorption rate
constant and apparent permeability coefficient of ITZ-Lip-
NaDC were generally higher than that of ITZ HP-β-CD in the
whole intestinal segments, where HP-β-CD was utilized to
improve ITZ solubility. Compared with 40 μg/mL and 20 μg/
mL ITZ-Lip-NaDC, the permeability of 80 μg/mL liposome is
reduced to 0.3-fold and 0.5-fold, respectively. Therefore, it is
reasonable to attribute the absorption phenomenon of ITZ-
Lip-NaDC to passive transport involved in active endocytosis
in the intestinal tract. Moreover, the passive diffusion of re-
leased ITZ might also participate in the absorption process.The
performance of single-pass intestinal infusion exhibited that
the transport order of intestinal segment was jejunum, duo-
denum, colon and ileum, and that all the segments participated
in the absorption of ITZ in intestinal tract.
3.4. Bioavailability study by UPLC-MS/MS
Two groups of rats were orally administrated with ITZ-Lip-
NaDC suspension and commercial capsules suspension
(dispersed into saline) at a dose of 20 mg/kg. The methodol-
ogy of ITZ in vivo by UPLC-MS/MS was conformed to the
standards, and the tested linearity ranged from 10 to 3000 ng/
mL with a correlation coefficient of 0.9965 with the standard
curve being Y = 0.03510X+0.05150.
As shown in Table 2 and Fig. 6, the AUC0-72 of ITZ-Lip-
NaDC and commercial capsules were 3484.6 ± 1658.2 ng/
mL·h and 5547.8 ± 1951.8 ng/mL·h, respectively. Moreover, the
RSD of AUC0-72 of ITZ-Lip-NaDC was around 35.1%, a decrease
in comparison with commercial capsules (about 47.6%).There-
fore, it might infer that ITZ-Lip-NaDC can improve oral
bioavailability of ITZ and reduce the variability of gastrointes-
tinal absorption, which might lie in gastrointestinal pH,
liposome protection and endocytosis pathways. In compari-
son with ITZ-Lip-NaDC formulation, commercial capsules might
reveal a poorer drug release behavior except pH 1.2 as esti-
mated from dissolution study, and the ionization of ITZ at pH
1.2 also restrains its transport across membrane. In addition,
the commercial capsules might be liable to the complex in-
testinal condition including the enzymes and mechanical
contraction because of lack of the shell protection of lipo-
some [35,36]. Moreover, ITZ-Lip-NaDC might be endocytosed
through nanoparticle endocytosis pathways on account of in-
volvement in the active endocytosis in intestinal tract due to
the penetration-enhancing effect of sodium deoxycholate,which
could be inferred from the results of in situ single-pass intes-
tinal infusion.
4. Conclusions
The liposome,mainly consisting of egg yolk lecithin and sodium
deoxycholate, was prepared by thin-film dispersion method,
and DSC demonstrated an amorphous state in the liposome.
The bioavailability study in rats showed that the AUC of the
liposome was nearly 1.67-fold higher than commercial cap-
sules (SPORANOX) in terms of oral administration. Our results
indicated that ITZ-Lip-NaDC liposome could be a potential oral
formulation of itraconazole, and the performance might shed
light on the design or development of oral delivery of lipo-
some preparations.
Fig. 5 – In situ absorption of ITZ-Lip-NaDC in different rat
intestinal segments compared with ITZ HP-β-CD complex
solution. (A) The absorption rate (Ka), (B) The apparent
permeability (Papp). Data were shown as mean + SD, n = 3.
Table 2 – Pharmacokinetic parameters of ITZ in rats after oral administration of commercial capsules and ITZ-Lip-NaDC








Commercial capsules 13.5 ± 8.0 270.9 ± 133.3 4.5 ± 2.3 3484.6 ± 1658.2
ITZ-Lip-NaDC 12.7 ± 5.7 416.5 ± 134.9 5.5 ± 2.1 5547.8 ± 1951.8
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